Management of coagulation during cardiopulmonary bypass

O'Carroll-Kuehn, Britta U.; Meeran, Hanif
December 2007
Continuing Education in Anaesthesia, Critical Care & Pain;Dec2007, Vol. 7 Issue 6, p195
Academic Journal
The article presents information on the management of coagulation during cardiopulmonary bypass. It states that coagulation and inflammatory pathways occur by contact of the blood with the cardiopulmonary bypass (CPB) circuit and surgical wound during open heart surgery. The mechanism of action of several anticoagulation for cardiopulmonary bypass like unfractionated heparin and heparin-induced thrombocytopenia and protamine is investigated. Also discussed is the monitoring anticoagulation and monitoring coagulation to guide hemostatic blood transfusion.


Related Articles

  • KardiohirurÅ¡ka procedúra kod bolesnika sa heparinom indukovanom trombocitopenijom (HIT II). Jović, M. D.; Nežić, D. G.; Čalija, B. M.; Nenadić, D. S.; Knežević, A. M.; Borzanović, M. D.; Krivokapić, B. M.; Petrović, I. M.; Djukanović, B. P. // Acta Chirurgica Iugoslavica;2009, Vol. 56 Issue 1, p47 

    Heparin-induced thrombocytopenia (HIT) might be life-threatening in patients undergoing open heart surgery, due to thromboembolic events, thrombocytopenia and bleeding. If cardiac surgery with cardiopulmonary bypass (CPB) is necessary, anticoagulation therapy will he based on usage of danaparoid...

  • Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin allergy. Pappalardo, F.; Franco, A.; G., G. Crescenzi; Poli, A.; Zangrillo, A.; Koster, A. // Perfusion;Jan2007, Vol. 22 Issue 1, p67 

    Heparin-induced IgE-mediated hypersensitivity and anaphylactoid reactions, although rare, can pose a serious clinical problem for patients requiring cardiopulmonary bypass (CPB). Bivalirudin is a bivalent reversible direct thrombin inhibitor, with a half-life of 25 min, eliminated mostly by...

  • A statistical analysis of factors predisposing patients to heparin resistance. Tanee Chan; Nian Chih Hwang; Chong Hee Lim // Perfusion;Mar2006, Vol. 21 Issue 2, p99 

    Heparin resistance (HR) is occasionally encountered in cardiac surgery. The objective of this study is to identify possible factors predisposing patients to heparin resistance. Four hundred patients scheduled for elective cardiac surgery requiring the use of cardiopulmonary bypass (CPB) were...

  • Comparison of ACT point-of-care measurements: repeatability and agreement. Bosch, Y. P. J.; Ganushchak, Y. M.; de Jong, D. S. // Perfusion;Jan2006, Vol. 21 Issue 1, p27 

    Background: Accurate control of heparin anticoagulation is necessary during all stages of cardiopulmonary bypass (CPB). The activated clotting time, first described by Hattersley in 1966, is mostly used for determination of anticoagulation. Either celite or kaolin are used as activators. An ACT...

  • Thrombocytopenia Associated with Antithrombotic Therapy in Patients with Cardiovascular Diseases: Diagnosis and Treatment. Kilickiran Avci, Burcak; Oto, Ali; Ozcebe, Osman // American Journal of Cardiovascular Drugs;2008, Vol. 8 Issue 5, p327 

    Agents with antiplatelet and anticoagulant activity have been proved to be effective in reducing the incidence of complications following acute coronary syndrome, percutaneous coronary intervention, and cardiopulmonary bypass. However, these agents, including heparin, glycoprotein IIb/IIIa...

  • Bivalirudin: Alternative Anticoagulation During Cardiopulmonary Bypass in Patients with Heparin-Induced Thrombocytopenia. Grubb, Kendra J.; Salehi, Payam; Chedrawy, Edgar G. // Recent Patents on Cardiovascular Drug Discovery;Jan2010, Vol. 5 Issue 1, p20 

    An estimated 1-3% of patients who receive therapeutic anticoagulation with unfractionated heparin (UFH) develop antibodies to heparin with concomitant development of thrombocytopenia, defined as HIT or Heparin-Induced Thrombocytopenia. HIT complicates the management of patients presenting for...

  • Delayed thrombin generation is not associated with fibrinopeptide formation during prolonged cardiopulmonary bypass with hirudin anticoagulation. Belway, D.; Rubens, F. D.; Henley, B.; Babaev, A.; Mesana, T. // Perfusion;Sep2006, Vol. 21 Issue 5, p259 

    Patients with heparin-induced thrombocytopenia urgently requiring surgery with cardiopulmonary bypass (CPB) present a unique management challenge that must be addressed by the use of alternative anticoagulants. Although clinical success with the direct thrombin inhibitor hirudin has been...

  • A Comparison of Heparin and New Anticoagulants for Cardiopulmonary Bypass Surgery. Belougne-Malfattie, Emmanuelle; Aguejouf, Omar; Labrousse, Louis; Doutremepuich, Christian // Clinical & Applied Thrombosis/Hemostasis;Apr1998, Vol. 4 Issue 2, p118 

    Heparin is still the major anticoagulant of choice during CPB. but it may cause thrombocytopenia and severe bleeding in patients. In light of these complications, the development of new anticoagulant drugs seemed to be necessary for these patients. Many experimental studies focused on r-hirudin,...

  • Coagulation and Anti-coagulation for Combined Heart Liver Transplant. Holigan, Jessica // International Student Journal of Nurse Anesthesia;Spring2015, Vol. 14 Issue 1, p6 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics